Results schedulesBSE · 500660
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Board Meeting Intimation for To Consider, Approve And Take On Record The Un-Audited Financial Results For The Second Quarter & Half Year Ended 30Th September 2026.
01 / The disclosure
What the company shared
Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve As per attachment
Exchange-provided summary Company profile
A question for your research
Confirm the meeting date and reporting period. A scheduled meeting or trading-window closure does not establish that results have been released.
Disclosed period ended 2026-09-30 · Q2 FY2027The evidence
Read the source excerpts
PDF text extraction is queued. The summary above comes from the exchange listing.
Source & verificationView the disclosure trail
- Summary method
- Exchange-provided text; no generated financial figures
- Exchange identifier
- c1ac4221-3fcf-4535-aa03-30087ed114ef
- First collected
- 13 Oct 2026, 16:19 IST
- PDF extraction
- pending
You’ve reached the end of this disclosure.